What are Value Stocks?
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labeled as a value stock.
Below is a list of notable value stocks in the healthcare sector:
- SELLAS Life Sciences Gr SLS - P/E: 0.62
- Supernus Pharmaceuticals SUPN - P/E: 9.78
- Ocugen OCGN - P/E: 0.04
- Oncternal Therapeutics ONCT - P/E: 4.61
- Coherus BioSciences CHRS - P/E: 7.01
SELLAS Life Sciences Gr has been featured as a value stock. SELLAS Life Sciences Gr's Q2 EPS sits at -0.66, which has not changed since last quarter (Q1). SELLAS Life Sciences Gr does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
Most recently, Supernus Pharmaceuticals reported earnings per share at 0.74, whereas in Q2 earnings per share sat at 0.65. Supernus Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
Ocugen has reported Q3 earnings per share at -0.02, which has increased by 89.47% compared to Q2, which was -0.19. Ocugen does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
Most recently, Oncternal Therapeutics reported earnings per share at -0.22, whereas in Q2 earnings per share sat at -0.34. Oncternal Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
Coherus BioSciences’s earnings per share for Q3 sits at 0.47, whereas in Q2, they were at 0.81. Coherus BioSciences does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.